Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study

Omega-3 (n-3) (e.g., EPA/DHA) and omega-6 (n-6) (e.g., linoleic acid [LA]) FAs are suggested to have opposite effects on inflammation, but results are inconsistent and direct comparisons of n-3 and n-6 are lacking. In a double-blind, randomized, and crossover study, females (n = 16) and males (n = 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Elise Grytten, Johnny Laupsa-Borge, Kaya Cetin, Pavol Bohov, Jan Erik Nordrehaug, Jon Skorve, Rolf K. Berge, Elin Strand, Bodil Bjørndal, Ottar K. Nygård, Espen Rostrup, Gunnar Mellgren, Simon N. Dankel
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227525000306
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850201071619670016
author Elise Grytten
Johnny Laupsa-Borge
Kaya Cetin
Pavol Bohov
Jan Erik Nordrehaug
Jon Skorve
Rolf K. Berge
Elin Strand
Bodil Bjørndal
Ottar K. Nygård
Espen Rostrup
Gunnar Mellgren
Simon N. Dankel
author_facet Elise Grytten
Johnny Laupsa-Borge
Kaya Cetin
Pavol Bohov
Jan Erik Nordrehaug
Jon Skorve
Rolf K. Berge
Elin Strand
Bodil Bjørndal
Ottar K. Nygård
Espen Rostrup
Gunnar Mellgren
Simon N. Dankel
author_sort Elise Grytten
collection DOAJ
description Omega-3 (n-3) (e.g., EPA/DHA) and omega-6 (n-6) (e.g., linoleic acid [LA]) FAs are suggested to have opposite effects on inflammation, but results are inconsistent and direct comparisons of n-3 and n-6 are lacking. In a double-blind, randomized, and crossover study, females (n = 16) and males (n = 23) aged 30–70 years with abdominal obesity were supplemented with 3–4 g/d EPA/DHA (fish oil) or 15–20 g/d LA (safflower oil) for 7 weeks, with a 9-week washout phase. Cytokines and chemokines (multiplex assay), acute-phase proteins (MALDI-TOF mass spectrometry), endothelial function (vascular reaction index), blood pressure, FA composition (red blood cell membranes/serum/adipose tissue, GC-MS/MS), and adipose gene expression (microarrays, quantitative PCR) were measured. While significant differences between treatments in relative change scores were found for systolic blood pressure (n-3 vs. n-6: −1.81% vs. 2.61%, P = 0.003), no differences between n-3 and n-6 were found for any circulatory inflammatory markers. However, compared with baseline, n-3 was followed by reductions in circulating TNF (−24.9%, P < 0.001), regulated upon activation, normal T cell expressed and secreted (−12.1%, P < 0.001), and macrophage inflammatory protein 1-beta (−12.5%, P = 0.014), and n-6 by lowered TNF (−18.8%, P < 0.001), regulated upon activation, normal T cell expressed and secreted (−7.37%, P = 0.027), monocyte chemoattractant protein-1 (−7.81%, P = 0.020), and macrophage inflammatory protein 1-beta (−14.2%, P = 0.010). Adipose tissue showed significant treatment differences in weight percent of EPA (n-3 vs. n-6: 50.2%∗ vs. −1.38%, P < 0.001, ∗: significant within-treatment change score), DHA (16.0%∗ vs. −3.67%, P < 0.001), and LA (−0.033 vs. 4.91%∗, P < 0.001). Adipose transcriptomics revealed overall downregulation of genes related to inflammatory processes after n-3 and upregulation after n-6, partly correlating with changes in circulatory markers. These data point to tissue-specific proinflammatory effects of high n-6 intake, but a net systemic anti-inflammatory effect as for n-3.
format Article
id doaj-art-ed17f71b376c49b28baaa2f13444c435
institution OA Journals
issn 0022-2275
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series Journal of Lipid Research
spelling doaj-art-ed17f71b376c49b28baaa2f13444c4352025-08-20T02:12:07ZengElsevierJournal of Lipid Research0022-22752025-04-0166410077010.1016/j.jlr.2025.100770Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover studyElise Grytten0Johnny Laupsa-Borge1Kaya Cetin2Pavol Bohov3Jan Erik Nordrehaug4Jon Skorve5Rolf K. Berge6Elin Strand7Bodil Bjørndal8Ottar K. Nygård9Espen Rostrup10Gunnar Mellgren11Simon N. Dankel12Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, NorwayHormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; Bevital AS, Bergen, NorwayHormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, Norway; Department of Heart Disease, Haukeland University Hospital, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Clinical Science, University of Bergen, Bergen, Norway; Department of Heart Disease, Haukeland University Hospital, Bergen, NorwayDepartment of Heart Disease, Haukeland University Hospital, Bergen, NorwayHormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, NorwayHormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway; Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; For correspondence: Simon N. DankelOmega-3 (n-3) (e.g., EPA/DHA) and omega-6 (n-6) (e.g., linoleic acid [LA]) FAs are suggested to have opposite effects on inflammation, but results are inconsistent and direct comparisons of n-3 and n-6 are lacking. In a double-blind, randomized, and crossover study, females (n = 16) and males (n = 23) aged 30–70 years with abdominal obesity were supplemented with 3–4 g/d EPA/DHA (fish oil) or 15–20 g/d LA (safflower oil) for 7 weeks, with a 9-week washout phase. Cytokines and chemokines (multiplex assay), acute-phase proteins (MALDI-TOF mass spectrometry), endothelial function (vascular reaction index), blood pressure, FA composition (red blood cell membranes/serum/adipose tissue, GC-MS/MS), and adipose gene expression (microarrays, quantitative PCR) were measured. While significant differences between treatments in relative change scores were found for systolic blood pressure (n-3 vs. n-6: −1.81% vs. 2.61%, P = 0.003), no differences between n-3 and n-6 were found for any circulatory inflammatory markers. However, compared with baseline, n-3 was followed by reductions in circulating TNF (−24.9%, P < 0.001), regulated upon activation, normal T cell expressed and secreted (−12.1%, P < 0.001), and macrophage inflammatory protein 1-beta (−12.5%, P = 0.014), and n-6 by lowered TNF (−18.8%, P < 0.001), regulated upon activation, normal T cell expressed and secreted (−7.37%, P = 0.027), monocyte chemoattractant protein-1 (−7.81%, P = 0.020), and macrophage inflammatory protein 1-beta (−14.2%, P = 0.010). Adipose tissue showed significant treatment differences in weight percent of EPA (n-3 vs. n-6: 50.2%∗ vs. −1.38%, P < 0.001, ∗: significant within-treatment change score), DHA (16.0%∗ vs. −3.67%, P < 0.001), and LA (−0.033 vs. 4.91%∗, P < 0.001). Adipose transcriptomics revealed overall downregulation of genes related to inflammatory processes after n-3 and upregulation after n-6, partly correlating with changes in circulatory markers. These data point to tissue-specific proinflammatory effects of high n-6 intake, but a net systemic anti-inflammatory effect as for n-3.http://www.sciencedirect.com/science/article/pii/S0022227525000306PUFAsomega-3omega-6inflammationendothelial functionblood pressure
spellingShingle Elise Grytten
Johnny Laupsa-Borge
Kaya Cetin
Pavol Bohov
Jan Erik Nordrehaug
Jon Skorve
Rolf K. Berge
Elin Strand
Bodil Bjørndal
Ottar K. Nygård
Espen Rostrup
Gunnar Mellgren
Simon N. Dankel
Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
Journal of Lipid Research
PUFAs
omega-3
omega-6
inflammation
endothelial function
blood pressure
title Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
title_full Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
title_fullStr Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
title_full_unstemmed Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
title_short Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study
title_sort inflammatory markers after supplementation with marine n 3 or plant n 6 pufas a randomized double blind crossover study
topic PUFAs
omega-3
omega-6
inflammation
endothelial function
blood pressure
url http://www.sciencedirect.com/science/article/pii/S0022227525000306
work_keys_str_mv AT elisegrytten inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT johnnylaupsaborge inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT kayacetin inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT pavolbohov inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT janeriknordrehaug inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT jonskorve inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT rolfkberge inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT elinstrand inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT bodilbjørndal inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT ottarknygard inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT espenrostrup inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT gunnarmellgren inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy
AT simonndankel inflammatorymarkersaftersupplementationwithmarinen3orplantn6pufasarandomizeddoubleblindcrossoverstudy